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ABSTRACT
Objective: This study aimed to investigate the anticancer profile of a new cyclin-dependent kinase 7
(CDK7) inhibitor, UD-017, by examining its mechanism of action using HCT-116 colorectal cancer cells.
Methods: The anticancer properties of UD-017 were assessed using several assays, including in vitro
kinase, proliferation, and apoptosis assays, western blot analysis, and an in vivo xenograft mouse model.
Results: UD-017 significantly inhibited CDK7 activity (IC50 = 16 nM) with high selectivity in an in vitro
kinase assay testing a panel of over 300 proteins and lipid kinases. UD-017 also inhibited the growth of
HCT-116 cells (GI50 = 19 nM) and inhibited the phosphorylation of various downstream mediators of CDK7
signaling. In cell cycle and apoptosis assays using HCT-116 cells, UD-017 increased the number of cells in
both G1 and G2/M phases and induced apoptosis. In vivo, UD-017 inhibited tumor growth in an HCT-116
xenograft mouse model by 33%, 64%, and 88% at doses of 25, 50, and 100 mg/kg, respectively, with clear
dose-dependency. Co-administration of 5-FU and 50 mg/kg UD-017 had a strong synergistic effect, as
reflected in the complete inhibition of tumor growth.
Conclusion: CDK7 may play a major role in colorectal cancer growth by regulating the cell cycle and apop-
tosis. UD-017 is a promising candidate therapeutic agent for the treatment of cancer involving CDK7 signal-
ing.
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INTRODUCTION
Cyclin-dependent kinases (CDK) are serine/threonine
kinases that regulate multiple cellular processes19). CDK7
was identified as a component of CDK-activating kinase
(CAK), which plays a pivotal role in cell cycle progres-
sion10). CAK phosphorylates threonine residues in the
activation segment (T-loop) of downstream CDKs,
including cdc-2/CDK1, CDK2, CDK4, and CDK6, and
modulates their activities25). CDK7 plays another impor-
tant role in transcription via phosphorylation of the
carboxyl-terminal domain (CTD) of RNA polymerase II
(RNAPII)1,5,11,16). Specifically, the general transcription
factor II (TFIIH) complex (containing CDK7 and cyclin
H) phosphorylates serine-5 of the CTD, thereby enhanc-
ing the association between the CTD and m7G RNA cap-
ping machinery1). TFIIH also phosphorylates the
serine-7 residue of the CTD and modulates pausing and
transcriptional termination5,11).
The super-enhancer, first proposed by Young et al.12) is
a huge cluster of enhancers and formed by transcription
factors and co-factors. The expression of several onco-
genes, including Myc, is regulated by super-
enhancers18,20). The inhibition of CDK7 downregulates
super-enhancer-mediated gene expression in cancer
cells, including the expression of Myc and other onco-
genes7).
To date, several CDK inhibitors (including the pan-
CDK inhibitor Flavopiridol) have been tested in clinical
trials and found to be highly toxic30). However, a number
of selective CDK4/6 inhibitors (e.g., Palbociclib, Riboci-
clib, and Abemaciclib) have been approved for the treat-
ment of breast cancer, with ongoing trials with other
types of cancer3,9,26). This suggests that the selective inhi-
bition of CDKs could be the key to reducing the cytotoxi-
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city observed with some CDK inhibitors.
CDK7 expression correlates with malignancy in many
cancers, such as gastric cancer28), esophageal squamous
cell carcinoma31), breast cancer23), and colorectal can-
cer34), suggesting that CDK7 is an attractive target for
cancer therapy. The present study aimed to evaluate the
pharmacodynamic properties and anticancer activity of
the highly selective, orally bio-available CDK7 inhibitor,
UD-017, in the context of colorectal cancer.
MATERIALS AND METHODS
Animals
Five-week-old female athymic BALB/cnu/nu nude mice
(CAnN.Cg-Foxn1nu/CrlCrlj) were obtained from Charles
River Laboratories Japan, Inc. (Kanagawa, Japan). All
animals were acclimatized to the laboratory environment
for about one week and were confirmed to be healthy
prior to use in experiments. The mice were housed in
barrier facilities and kept under controlled environmen-
tal conditions at a room temperature of 23 ± 2°C and 55
± 10% humidity on a 12-hr light/dark cycle with ventila-
tion (15 air changes/hr). The mice were fed with a regu-
lar γ-ray-sterilized chow diet and 0.5 μm filtered water
ad libitum via water bottles (which were replaced twice a
week). All experimental protocols were reviewed and
approved by the Animal Care and Use Committee of the
Pharmaceuticals Research Laboratory of Ube Industries
Ltd.
Compound
UD-017 was synthesized at the Drug Research Insti-
tute, Research and Development Division, Ube Indus-
tries Ltd. (described in International Patent Publication
WO2016/204153A1). 5-Fluorouracil (5-FU) was pur-
chased from Wako Pure Chemical Industries, Ltd.
(Osaka, Japan).
Kinase panel assay
The ability of UD-017 (1,000 nM) to inhibit kinases
was tested against a panel of 313 kinases by either an off-
chip mobility shift assay or IMAP assay (Molecular
Devices LLC., Sunnyvale, USA). For AMPKα2/β1/γ1,
AMPKα1/β1/γ1, GSK3β, and CDKs, additional inhibi-
tion tests were conducted by optimal range of concentra-
tions to decide the concentration of UD-017 required to
suppress each enzyme by 50% (IC50). These assays were
performed by Carna Biosciences, Inc. (Kobe, Japan). IC50
was calculated using the EXSUS (Version 8.1; CAC Croit
Corporation. Tokyo, Japan) statistical analysis system.
Cell proliferation assay (cancer cell line panel)
All cell lines were obtained from the American Type
Culture Collection (ATCC, Manassas VA, USA). An assay
stock was thawed and diluted in ATCC-recommended
medium and was dispensed in a 384-well plate. Plated
cells were incubated in 5% CO2 at 37°C. After 24 hrs,
diluted UD-017 was added, and the plates were further
incubated for another 72 hrs. After incubation, the cells
were counted according to ATP quantity, and GI50 values
(concentrations that produced 50% growth inhibition)
were calculated from the dose-response sigmoidal curve.
These cell proliferation assays were performed using
OncolinesTM (Netherlands Translational Research Center
B.V., Oss, Netherlands).
Cell culture (HCT-116 cells)
HCT-116 cells (colorectal cancer cell line) were
obtained from DS Pharma BioMedical (EC91091005-F0)
and cultured in McCoy’s 5A medium (16600-082,
GIBCO) supplemented with 10% fetal bovine serum
(11082, GIBCO) and 1% antibiotic–antimycotic solution
(15240-096, GIBCO). Cells were incubated in a humidi-
fied atmosphere of 5% CO2 at 37°C.
Western blot analysis (in vitro experiments)
HCT-116 cells were lysed in RIPA buffer (9806S, Cell
Signaling Technology, Danvers, USA) or M-PER (78510,
Thermo Fisher Scientific, Inc., Waltham, USA) that con-
tained both protease inhibitors (Complete Mini, Roche
Diagnostics, Mannheim, Germany) and phosphatase
inhibitors (Complete PhosSTOP, Roche Diagnostics,
Mannheim, Germany). Cell lysates were subjected to
SDS-PAGE and western blot analysis. Immunoblots were
probed with primary antibodies and subsequently with
their respective horseradish peroxidase–conjugated sec-
ondary antibodies. The primary antibodies used were as
follows: anti-GAPDH antibody (2118S), anti-Rb anti-
body (9309S), anti-phospho-Rb S780 antibody (8180S),
anti-phospho-Rb S807/811 antibody (8516S), anti-cdc2
antibody (9112S), anti-phospho-cdc2 Thr161 antibody
(9116S), anti-CDK2 antibody (2546S), anti-phospho-
CDK2 Thr160 (2561S), anti-c-Myc antibody (5605S),
anti-PARP antibody (9542), and anti-XIAP antibody
(2042), all of which were purchased from Cell Signaling
Technology, Inc. The anti-phospho-Rb S795 antibody
(ab47474) and anti-RNAPII antibody (ab817) were pur-
chased from Abcam, and the anti-RNAPII CTD P-ser2
antibody (04-1571), anti-RNAPII CTD P-ser5 antibody
(04-1572), and anti-RNAPII CTD P-ser7 antibody
(04-1570) were purchased from Merck Millipore Corpo-
ration. Immunoblots were developed with the Amer-
shamTM ECLTM Prime Western Blotting Detection
Reagent (GE Healthcare, Buckinghamshire, UK), and
chemiluminescence was captured with a ChemiDocTM
XRS System (Bio-Rad Laboratories, Inc., Hercules,
USA).
Cell cycle assay
HCT-116 cells were seeded in six-well plates and
allowed to adhere overnight. DMSO or UD-017 was
added to the cells for 8 hrs, after which cells were col-
lected and treated in accordance with the manufacturer’s
protocol (Cell-Cycle Phase Determination Kit, 10009349,
Cayman Chemical Company, Ann Arbor, USA). A mini-
mum of 10,000 events were collected per sample for flow
cytometry analysis (FACSCalibur, Becton Dickinson,
Franklin Lakes, USA). Cell cycle analysis was performed
using ModFit LT software (Verity Software House, Top-
sham, USA). Data are presented as mean values (n = 2).
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Apoptosis assay
HCT-116 cells were seeded onto plates overnight. The
following day, UD-017 was added to each well at final
concentrations of 100, 300, 1,000, 3,000, and 10,000
nM, and DMSO was added as a control (final DMSO con-
centration: 0.1%). The cells were then incubated for 72
hrs. The culture medium was removed after incubation
and the cells were collected. FITC Annexin V and propid-
ium iodide (PI) were added to the cells (FITC Annexin V
apoptosis detection kit I, 556547, BD Pharmingen, San
Jose, USA). After incubation, the cells were analyzed
within 1 hr by flow cytometry. Data are presented as
mean values ± SD (n = 3–6).
Xenograft mouse model
HCT-116 cells were harvested and diluted in
phosphate-buffered saline to produce a cell suspension
of 1 × 107 cells/100 μl. The cell suspensions (100 μl/
mouse) were injected into the right flanks of mice. At 6–
7 days after injection, tumor volume (mm3) was calcu-
lated as follows: ([Ma] × [Mi] × [Mi])/2 (where Ma is the
length of the major axis, and Mi is the length of the
minor axis). Once tumors reached a size of about 100
mm3, the mice were selected and grouped so that the
mean tumor volumes of all groups (n = 6) were approxi-
mately equal. UD-017 was suspended in 0.5% (w/v)
methyl cellulose 400 solution and orally administered
daily from day 0 to day 13 for two weeks. 5-fluorouracil
(5-FU) was dissolved in a glucose injection solution
(20%, Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan)
and intraperitoneally administered at a dose of 15 mg/kg
daily for two weeks. During the experiments, mice were
weighed and tumors were measured twice weekly. Data
are presented as mean values ± SEM (n = 6).
Western blot analysis (in vivo)
Fourteen days after HCT-116 cell injection, mice were
orally administered 25, 50, or 100 mg/kg of UD-017 or
vehicle. Two hours after administration of a single dose,
tumors were collected under isoflurane anesthesia. T-
PER (78510, Thermo Fisher Scientific Inc.) and a Halt
protease and phosphatase inhibitor cocktail (100×) were
mixed at a ratio of 100:1 to prepare the lysis buffer. Pro-
tein lysates from tumors were subjected to SDS-PAGE
and Western blot analysis. Immunoblots were probed
with primary antibodies (anti-GAPDH antibody [2118S],
Figure 1 In vitro properties of UD-017 as a CDK7 inhibitor. (A) Evaluation of UD-017 selectivity for various kinases. Tests were
performed to determine if 1,000 nM of UD-017 showed inhibition with 313 kinases. IC50 values were calculated for kinases that
showed more than 50% inhibition at 1,000 nM of UD-017. (B) Selectivity of UD-017 for various CDK subtypes. (C) GI50 values of
UD-017 against colorectal cancer cell lines.
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anti-c-Myc antibody [5605S], anti-Rb [4H1], anti-
phospho-Rb [Ser780] [D59B7], and anti-PARP antibody
[9542S] from Cell Signaling Technology Inc.; anti-RNA
pol2 antibody [ab817] from Abcam; and anti-RNA pol2
CTD P-ser5 antibody [04-1572] from Merck Millipore
Corporation), followed by their respective horseradish
peroxidase-conjugated secondary antibodies.
Immunoblots were developed using the AmershamTM
ECLTM Prime Western Blotting Detection Reagent (GE
Healthcare) and chemiluminescence was captured with a
ChemiDocTM XRS System (Bio-Rad Laboratories).
Densitometry
Analysis of the bands on films was performed using
Image Lab (Molecular Imager® ChemiDocTM XRS). The
target band was identified based on molecular weights of
both the target protein and the detected band. Using this
software, band densities were quantified at an appropri-
ate interval and output.
Statistical analysis
Statistical analyses were performed with EXSUS soft-
ware using analysis of variance followed by Dunnett’s
multiple test. P-values less than 0.05 were considered
significant.
RESULTS
Kinase selectivity of UD-017
The kinase selectivity of UD-017 was tested using the
off-chip mobility shift assay or IMAP assay. UD-017 at
1,000 nM was highly selective for CDK7 among the 313
kinases tested (Figure 1A). Only four kinases
(AMPKα2/β1/γ1, AMPKα1/β1/γ1, GSK3β, and Haspin)
were inhibited by more than 50% at UD-017 concentra-
tions < 1,000 nM, but the IC50 values for these kinases
were still ≥ 20-fold higher than that for CDK7. Selectivity
among CDK subtypes was also confirmed. IC50 values for
CDK7 were ≥ 300-fold higher than for other CDKs,
including CDK1, CDK2, CDK3, CDK4, CDK5, CDK6, and
CDK9 (Figure 1B).
Antiproliferative activity of UD-017
The antiproliferative effect of UD-017 was initially
tested against a panel of cancer cell lines (OncolinesTM).
UD-017 showed significant growth inhibition with a GI50
of 19 nM for HCT-116 cells (Figure 1C). We next looked
into the mechanism underlying the antiproliferative
activity of UD-017. CDK7 is a member of the cyclin-
dependent kinase family and regulates the activities of
other CDKs (such as CDK1, CDK2, and CDK4/6) by
phosphorylating their activation segments. The phospho-
rylation of retinoblastoma (Rb) by CDK2 or CDK4/6
controls the cell cycle. Therefore, we tested the effect of
UD-017 on the phosphorylation of CDKs and Rb in
HCT-116 cells. Treating HCT-116 cells with 100 and
1,000 nM of UD-017 for 8 hrs and 24 hrs reduced CDK-1
and CDK-2 phosphorylation. The suppression of Rb
phosphorylation at CDK4/6-specific sites (Ser780 and
Ser807/811)32) suggests that UD-017 inhibited the activ-
ities of CDK4/6 (Figure 2A). Cell cycle analyses revealed
that HCT-116 cells treated with 100 nM and 1,000 nM of
Figure 2 Mechanism of the antiproliferative activity of UD-017 in HCT-116 cells. (A) Effect of UD-017 on the phosphorylation of
CDKs and Rb protein in HCT-116 cells at 8 and 24 hr after treatment. CDK1, pCDK1, CDK2, pCDK2: 34 kDa. Rb, pRb: 110 kDa.
GAPDH: 37 kDa. (B) Effect of UD-017 on cell cycle progression in HCT-116 cells at 8 hr after treatment (n = 2). The band density
was quantified. Each ratio was calculated and normalized with DMSO control.
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UD-017 for 8 hrs increased the number of cells in both
G1 and G2/M phases (Figure 2B).
Effects of UD-017 on transcriptional machinery
and oncogene expression
CDK7 phosphorylates serine in the CTD of RNAPII
and controls transcriptional initiation and elongation by
RNAPII1,5,11,16). In this experiment, we examined the
effects of UD-017 on RNAPII phosphorylation in
HCT-116 cells. As shown in Figure 3A, UD-017 potently
inhibited serine 5 phosphorylation of RNAPII for up to
72 hrs after treatment, but did not inhibit serine 7 phos-
phorylation.
Given reports that transcriptional inhibition by CDK7
has a large effect on the expression of oncogenes such as
Myc7), we also examined c-Myc expression. c-Myc
expression was inhibited by UD-017 at 100 and 1,000
nM in HCT-116 cells (Figure 3B). This suggests that sup-
pression of transcription through the inhibition of
RNAPII phosphorylation by UD-017 might lead to a sus-
tained inhibition of c-Myc expression.
Effects of UD-017 on apoptosis
The expression of apoptotic signaling proteins in
HCT-116 cells at 72 hrs after treatment with UD-017
was examined. At concentrations ≥ 100 nM, the expres-
sion of XIAP, an anti-apoptotic molecule, decreased, and
PARP cleavage increased in a dose-dependent manner
(Figure 3C). Given the activation of apoptotic signaling,
the proportion of Annexin V-positive and PI-negative
Figure 3 Apoptosis induction of UD-017 in HCT-116 cells. (A) Effect of UD-017 on phosphorylation of RNAPII in HCT-116 cells
at 1 to 72 hr after treatment. RNAPII, pRNAPII: 240 kDa. (B) Effect of UD-017 on Myc expression in HCT-116 cells at 1 to 72 hr
after treatment. c-Myc: 57–65 kDa. (C) Expression of apoptosis signal proteins at 72 hr after treatment with UD-017 in HCT-116
cells. XIAP: 53 kDa, PARP: 116 kDa, cleaved PARP: 89 kDa. (D) Apoptosis induction in HCT-116 cells at 72 hr after treatment with
UD-017 (n = 3–6). The band density was quantified. Each ratio was calculated and normalized with DMSO control. Data are mean
± SD; Dunnett’s multiple test using EXSUS, ***: P < 0.001.
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cells (which reflect early apoptotic cells) was investigated
using flow cytometry. As shown in Figure 3D, UD-017
induced apoptosis from a concentration of 100 nM, with
the increase becoming significant at concentrations
above 1,000 nM.
Anticancer effect of UD-017 in vivo
Since UD-017 exhibited antiproliferative effects in
vitro, we next tested whether UD-017 has anticancer
effects in vivo using an HCT-116 xenograft mouse
model. Daily single doses of UD-017 at 25, 50, and 100
mg/kg inhibited cancer growth by 33%, 64%, and 88%,
respectively, with clear dose-dependency over the course
of 14 days (Figure 4A). Throughout the experiment,
UD-017 was well tolerated, with no reduction in body
weight (Figure 4B).
To gain a better understanding of the mechanism
underlying the anticancer effect of UD-017 after single
dosing, the expression levels of various proteins in
tumors were assessed at 2 hrs after UD-017 administra-
tion. Similar to the in vitro experiments, phosphoryla-
tion of Rb at S780 was inhibited, reflecting cell cycle
arrest (Figure 5A). UD-017 also inhibited RNAPII phos-
phorylation and c-Myc expression starting at a dose of
25 mg/kg. PARP cleavage was detected from 50 mg/kg
(Figure 5B). These findings suggest that UD-017 induces
apoptosis both in vitro and in vivo.
Combination therapy with UD-017 and 5-FU
Since 5-FU is the standard drug used for chemother-
Figure 4 Anticancer activity of UD-017 in an HCT-116 xenograft model mouse. (A) In vivo anticancer activity of UD-017 after 14
days of treatment. (B) Body weight change of mouse after UD-017 treatment. Data are mean ± SE (n = 6); Dunnett’s multiple test
using EXSUS, *p < 0.05, **p < 0.01, ***p < 0.001 versus “vehicle group.”
Figure 5 Mechanism of the anticancer activity of UD-017 in an HCT-116 xenograft model mouse. (A) Phosphorylation of Rb pro-
tein at 2 hr after UD-017 single administration (100 mg/kg). Rb, pRb: 110 kDa. NC: not calculated. (B) Phosphorylation of RNAPII
protein and expression level of c-Myc and PARP cleavage at 2 hr after UD-017 single administration (25, 50, 100 mg/kg). RNAPII,
pRNAPII: 240 kDa. c-Myc: 57–65 kDa. PARP: 116 kDa, cleaved PARP: 89 kDa. The band density was quantified and each ratio was
calculated.
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apy in colorectal cancer, we tested the combined effect of
UD-017 with 5-FU. Tumor-bearing mice were treated
with 15 mg/kg i.p. of 5-FU alone, 50 mg/kg of UD-017
alone, or UD-017 plus 5-FU. As shown in Figures 6A and
6B, an additive effect on the reduction of tumor volume
was observed with the combination of UD-017 with 5-
FU, with no side effects.
DISCUSSION
This is the first report of the anticancer effects of
UD-017, a newly identified, orally bio-available, potent,
and selective CDK7 inhibitor. UD-017 has been shown to
exhibit anticancer effects by inducing cell cycle arrest
and apoptosis. Several CDK7 inhibitors have been shown
to have marked anticancer effects in preclinical stud-
ies2,8,13,17,27,33). There is also a currently ongoing trial of
CT7001, another orally bio-available selective CDK7
inhibitor, for breast cancer24).
Testing the inhibitory activity of UD-017 against a
panel of 313 kinases revealed that UD-017 showed mini-
mal inhibition of kinases other than CDK7, demonstrat-
ing its high specificity for CDK7. This supports the low
risk of UD-017 in terms of inducing unexpected adverse
reactions resulting from the inhibition of other kinases4).
Unlike THZ1 (which covalently binds to CDK78)), the
inhibition of CDK7 by UD-017 is reversible (data not
shown). Thus, UD-017 has a very favorable profile with
regard to efficacy and toxicity.
UD-017 was found to inhibit the phosphorylation of
CDK1, CDK2, and Rb (Ser780, Ser795, and
Ser807/811), and slightly increased the proportion of
cells in G1 and G2/M phases. The modest effect on arrest
at specific cell cycle phases could reflect the fact that
UD-017 caused cell cycle arrest as a whole, rather than at
a particular phase. According to recent studies, some
cancers have acquired resistance to CDK4/6 inhibitors22).
Since the role of CDK7 is not limited to the G1 phase of
the cell cycle, CDK7 inhibitors may be effective against
cancers resistant to CDK4/6 inhibitors. In addition to its
effect on the cell cycle, UD-017 suppressed transcription
by inhibiting the phosphorylation of RNAPII, regulated
the expression of an apoptosis-related protein (XIAP),
and induced apoptosis. These findings collectively sug-
gest that UD-017 selectively inhibits CDK7 and exerts an
anticancer effect by arresting the cell cycle and inducing
apoptosis both in vitro and in vivo. This mechanism of
action has also been reported for other CDK7
inhibitors13,15,24).
Myc inhibition is an attractive target for cancer treat-
ment. However, directly inhibiting Myc is difficult
because it structurally lacks a pocket for modulators and
has a short life29). One practical approach to inhibiting
Myc is to regulate its expression29). For example, small-
molecule ligands targeting c-Myc promoter G-
quadruplexes and small-molecule inhibitors of c-
Myc/Max/DNA complex formation have been reported6).
CDK7 regulates the super-enhancer-driven transcription
of Myc and other oncogenes7). In the present study, we
demonstrated that UD-017 inhibits the phosphorylation
of PNAPII, suppresses c-Myc expression, and induces
apoptosis in HCT-116 cells. These findings suggest that
the inhibition of CDK7 may be a viable approach to sup-
press Myc expression.
Oral administration of UD-017 inhibited tumor
growth in the HCT-116 xenograft mouse model in a
dose-dependent manner. According to one in vitro
study, the activation of p53 by 5-FU synergized with a
CDK7 inhibitor to induce cell death14). Another in vitro
study reported that a CDK4/6 inhibitor showed synergis-
tic effects on cancer cells when combined with 5-FU by
modulating thymidylate synthase expression21). How-
ever, to our knowledge, there are no reports of highly
selective CDK7 inhibitors showing synergistic effects
with 5-FU in in vivo models. In this study, we demon-
strated the synergistic effects of UD-017 in combination
with 5-FU in the HCT-116 xenograft mouse model. Co-
administration of UD-017 and 5-FU may induce apopto-
sis more strongly through p53 activation and affect the
expression of thymidylate synthase, although this will
Figure 6 The combination effect of UD-017 with 5-FU in an HCT-116 xenograft model mouse. (A) In vivo anticancer activity of
UD-017 with 5-FU after 14 days of treatment. (B) Body weight change of mouse after UD-017 with 5-FU treatment. Data are mean
± SE (n = 6); Dunnett’s multiple test using EXSUS, *p < 0.05, “UD-017 50 mg/kg + 5-FU 15 mg/kg” group versus “UD-017 50
mg/kg” group.
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need to be evaluated in future studies.
In conclusion, the highly selective CDK7 inhibitor,
UD-017, significantly inhibited the proliferation of a
human colorectal cancer cell line (HCT-116) by inducing
cell-cycle arrest and apoptosis, and by regulating gene
expression, both in vitro and in vivo (Figure 7). We
anticipate that UD-017 will show anticancer effects in
clinical trials through this mechanism.
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